News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shenogen Pharma Group of Beijing Raises $20 Million in C Round


8/6/2013 8:00:04 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 5, 2013 -- Shenogen Pharma of Beijing raised $20 million in a series C funding, which the company will use to support a Phase II trial of its lead drug candidate, icaritin, a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer. The drug is derived from barrenwort, a TCM. The funding was led by Legend Capital and Qiming Weichuang Venture Capital. The investors also received warrants to buy an additional $10 million in shares. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES